CHMP fandt derfor, at de gavnlige virkninger opvejer de identificerede risici, ligesom det er tilfældet for Eprex/ Erypo.
Therefore, the CHMP’ s view was that, as for Eprex/ Erypo, the benefit outweighs the identified risks.